IP Library Granted Patent US 8,674,118
Granted Patent B2
US 8,674,118 · App. 13/416,565 · Granted Mar 18, 2014

Compounds and methods for the treatment or prevention of flavivirus infections

Inventors: Real Denis (Montreal, CA); Carl Poisson (Montreal, CA); Sanjoy Kumar Das (Pierrefonds, CA); Irina Motorina (Blainville, CA); Rabindra Rej (Montreal, CA); Constantin G. Yannopoulos (Ile Perrot, CA); Laval Chan Chun Kong (Kirkland, CA)
Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,674,118
App. No.
13/416,565
Granted
Mar 18, 2014
Kind
B2
Abstract

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R 1 , X, Y, Y 1 , and Z are as defined herein, are useful for treating flaviviridae viral infections.

Claims (39)

1. A process for preparing a compound of formula (I)

comprising reacting a compound of formula (II):

with a compound of formula R 1 —B(OH) 2 or R 1 —Bi,

wherein,

R 1 is chosen from optionally substituted C 3-12 cycloalkyl, optionally substituted —C(O)—C 3-12 cycloalkyl, optionally substituted 5 to 12 member spiroheterocycloalkyl and optionally substituted 8 to 12 member spiroheterocycloalkenyl;

X is chosen from:

M is chosen from:

 and a bond;

R 2 , R 3 and R 6 are each independently chosen from H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl, optionally substituted C 7-16 aralkyl, optionally substituted 5-12 member heteroaryl, optionally substituted 6-18 member heteroaralkyl, optionally substituted 3-12 member heterocycle, and optionally substituted 4-18 member heterocycle-alkyl;

R 4 and R 5 are each independently chosen from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl and optionally substituted C 2-6 alkynyl;

Y 1 is a bond, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;

Y is COOR 9 , COCOOR 9 , P(O)OR a OR b , S(O)OR 9 , S(O) 2 OR 9 , tetrazole, CON(R 9 )CH(R 9 )COOR 9 , CONR 10 R, R 11 , CON(R 9 )—SO 2 —R 9 , CONR 9 OH, or halogen;

J is chosen from:

R 7 is chosen from H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl optionally substituted, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl and optionally substituted C 7-16 aralkyl;

W is chosen from O, S and NR 8 ;

R 8 is chosen from H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl, optionally substituted C 7-16 aralkyl, optionally substituted 5-12 member heteroaryl, optionally substituted 6-18 member heteroaralkyl, optionally substituted 3-12 member heterocycle, and optionally substituted 4-18 member heterocycle-alkyl;

R 9 , R 10 and R 11 are each independently chosen from H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl, optionally substituted C 7-16 aralkyl, optionally substituted 5-12 member heteroaryl, optionally substituted 6-18 member heteroaralkyl, optionally substituted 3-12 member heterocycle, or optionally substituted 4-18 member heterocycle-alkyl,

or R 10 and R 11 are taken together with the nitrogen atom to form an optionally substituted 3 to 10 member heterocycle or an optionally substituted 5-12 member heteroaryl;

Pg 1 is OH, methoxy or a carboxyl protecting group;

Hal is Cl, Br, or I; and

B 1 is a boronate;

under Suzuki coupling conditions to form a compound of formula (I).

2. The process according to claim 1 , wherein Hal is Br.

3. The process according to claim 1 , wherein Pg 1 is methoxy.

4. The process according to claim 1 , wherein R 1 is optionally substituted C 3-12 cycloalkyl.

5. The process according to claim 1 , wherein X is

and M is

or a bond.

6. The process according to claim 5 , wherein M is

7. The process according to claim 1 , wherein R 2 is optionally substituted C 1-12 alkyl.

8. The process according to claim 7 , wherein R 2 is optionally substituted cyclohexyl.

9. The process according to claim 8 , wherein R 2 is methylcyclohexyl.

10. The process according to claim 1 , wherein R 3 is optionally substituted C 1-12 alkyl.

11. The process according to claim 10 , wherein R 3 is optionally substituted cyclohexyl.

12. The process according to claim 11 , wherein R 3 is hydroxycyclohexyl or methoxycyclohexyl.

13. The process according to claim 1 , wherein R 1 —B(OH) 2 is

14. The process according to claim 1 , wherein Y 1 is a bond.

15. The process according to claim 1 , wherein Y is COOH, CONH 2 , CONHCH 2 COOH, or COOCH 3 .

16. The process according to claim 1 , wherein R 9 , R 10 , and R 11 are each independently H or methyl.

Assignments (2)
MERGER Recorded May 3, 2012
From: VIROCHEM PHARMA INC.
To: VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
Reel/Frame 028148/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2012
From: DENIS, REAL; POISSON, CARL; KUMAR DAS, SANJOY; MOTORINA, IRINA; REJ, RABINDRA; YANNOPOULOS, CONSTANTIN G.; CHAN CHUN KONG, LAVAL
To: VIROCHEM PHARMA, INC.
Reel/Frame 028148/0882 →
Continuity (4)
Continuation 12508893 · Jul 24, 2009
Continuation 11433749 · May 15, 2006
Provisional Application 60680482 · May 13, 2005
Related Publication 20120164103A1 · Jun 28, 2012